Many P-glycoprotein substrates do not inhibit the transport process across cell membranes

Xenobiotica

Volumn 33, Issue 2, 2003, Pages 131-140

  Barecki Roach, M ^a   Wang, Er Jia ^a   Johnson, W W ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROGENIC ACID; CIMETIDINE; CIPROFLOXACIN; COLCHICINE; CYCLOSPORIN A; DAUNORUBICIN; DEBRISOQUINE; DEXAMETHASONE; DIGOXIN; EPIGALLOCATECHIN GALLATE; ERYTHROMYCIN; GLYCOPROTEIN P; LEVODOPA; LIDOCAINE; NORFLOXACIN; PROCAINAMIDE; PUROMYCIN; RHODAMINE 123; TRIBUTYLMETHYLAMMONIUM; VALINOMYCIN; VERAPAMIL; VINBLASTINE; XENOBIOTIC AGENT;

ANIMAL CELL; ARTICLE; BINDING SITE; CELL MEMBRANE TRANSPORT; CONCENTRATION (PARAMETERS); DIFFUSION; ENZYME INHIBITION; ENZYME SUBSTRATE COMPLEX; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PROTEIN FUNCTION;

3T3 CELLS; ADENOSINE TRIPHOSPHATE; ALGORITHMS; ANIMALS; BIOLOGICAL MARKERS; BIOLOGICAL TRANSPORT, ACTIVE; CELL MEMBRANE; CELL SURVIVAL; FLOW CYTOMETRY; KINETICS; MICE; MICROSOMES, LIVER; P-GLYCOPROTEINS; PHOSPHATES;

ANIMALIA;

EID: 0037327089     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/0049825021000035326     Document Type: Article

References (52)

1. AMBUDKAR, S. V., CARDARELLI, C. O., PASHINSKY, I. and STEIN, W. D., 1997, Relation between the turnover number for vinblastine transport and for vinblastine-stimulated ATP hydrolysis by human P-glycoprotein. Journal of Biological Chemistry, 272, 21160-21166.
2. AMBUDKAR, S. V., DEY, S., HRYCYNA, C. A., RAMACHANDRA, M., PASTAN, I. and GOTTESMAN, M. M., 1999, Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annual Reviews in Pharmacology and Toxicology, 39, 361-398.
3. BARNES, K. M., DICKSTEIN, B., CUTLER, G. B., JR, FOJO, T. and BATES, S. E., 1996, Steroid treatment, accumulation, and antagonism of P-glycoprotein in multidrug-resistant cells. Biochemistry, 35, 4820-4827.
4. BORGNIA, M. J., EYTAN, G. D. and ASSARAF, Y. G., 1996, Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. Journal of Biological Chemistry, 271, 3163-3171.
5. BORREL, M. N., FIALLO, M., VERESS I. and GARNIER-SUILLEROT, A., 1995, The effect of crown ethers, tetraalkylammonium salts, and polyoxyethylene amphiphiles on pirarubicin incorporation in K562 resistant cells. Biochemical Pharmacology, 50, 2069-2076.
6. CARULLI, G., PETRINI, M., MARINI, A., VAGLINI, F., CARACCIOLO, F. and GRASSI, B., 1990, P-glycoprotein and drug resistance in acute leukemias and in the blastic crisis of chronic myeloid leukemia. Haematologica, 75, 516-521.
7. CHIBA, P., ECKER, O., SCHMID, D., DRACH, J., TELL, B., GOLDENBERG, S. and GEKELER, V., 1996, Structural requirements for activity of propafenone-type modulators in P-glycoprotein-mediated multidrug resistance. Molecular Pharmacology, 49, 1122-1130.
8. COLLETT, A., HIGGS, N. B., SIMS, E., ROWLAND, M. and WARHURST, G., 1999, Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2. Journal of Pharmacology and Experimental Therapeutics, 288, 171-178.
9. DOPPENSCHMITT, S., SPAHN-LANGGUTH, H., REGARDH, C. G. and LANGGUTH, P., 1999, Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein. Journal of Pharmaceutical Science, 88, 1067-1072.
10. EYTAN, G. D., REGEV, R. and ASSARAF, Y. G., 1996a, Functional reconstitution of P-glycoprotein reveals an apparent near stoichiometric drug transport to ATP hydrolysis. Journal of Biological Chemistry, 271, 3172-3178.
11. EYTAN, G. D., REGEV, R., OREN, G. and ASSARAF, Y. G., 1996b, The role of passive transbilayer drug movement in multidrug resistance and its modulation. Journal of Biological Chemistry, 271, 12897-12902.
12. EYTAN, G. D., REGEV, R., OREN, G., HURWITZ, C. D. and ASSARAF, Y. G., 1997, Efficiency of P-glycoprotein-mediated exclusion of rhodamine dyes from multidrug-resistant cells is determined by their passive transmembrane movement rate. European Journal of Biochemistry, 248, 104-112.
13. FERTE, J., 2000, Analysis of the tangled relationships between P-glycoprotein-mediated multidrug resistance and the lipid phase of the cell membrane. European Journal of Biochemistry, 267, 277-294.
14. FERTE, J., KUHNEL, J. M., CHAPUIS, O., ROLLAND, Y., LEWIN, G. and SCHWALLER, M. A., 1999, Flavonoid-related modulators of multidrug resistance: synthesis, pharmacological activity, and structure-activity relationships. Journal of Medical Chemistry, 42, 478-489.
15. FISHER, G. A., LUM, B. L., HAUSDPR, J. and SIKIC, B. I. 1996, Pharmacological considerations in the modulation of multidrug resistance. European Journal of Cancer, 32A, 1082-1088.
16. GOTTESMAN, M. M. and PASTAN, I., 1993, Biochemistry of multidrug resistance mediated by the multidrug transporter. Annual Reviews of Biochemistry, 62, 385-427.
17. GOTTESMAN, M. M., PASTAN, I. and AMBUDKAR, S. V., 1996, P-glycoprotein and multidrug resistance. Current Opinions in Genetic Development, 6, 610-617.
18. ITO, K., KUSLUHABA, H. and SUGIYAMA, Y., 1999, Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption - theoretical approach. Pharmaceutical Research, 16, 225-231.
19. LENTZ, K. A., POLLI, J. W., WRING, S. A., HUMPHREYS, J. E. and POLLI, J. E., 2000, Influence of passive permeability on apparent P-glycoprotein kinetics. Pharmaceutical Research, 17, 1456-1460.
20. LOWRY, O. H., ROSEBRUGH, N. J., FARR, A. L. and RANDALL, R. J., 1951, Protein measurement with the folin phenol reagent. Journal of Biological Chernistry, 193, 265-275.
21. MANKHETKORN, S., DUBRU, F., HESSCHENBROUCK, J., FIALLO, M. and GARNIER-SUILLEROT, A., 1996, Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells. Molecular Pharmacology, 49, 532-539.
22. MANKHETKORN, S. and GARNIER-SUILLEROT, A., 1998, The ability of verapamil to restore intracellular accumulation of anthracyclines in multidrug resistant cells depends on the kinetics of their uptake. European Journal of Pharmacology, 343, 313-321.
23. PAY, B. F., DUTT, A. and NELSON, J. A., 1994, Enhanced transepithelial flux of cimetidine by Madin-Darby canine kidney cells overexpressing human P-glycoprotein. Journal of Pharrnacology and Experimental Therapeutics, 270, 1-7.
24. POLLI, J. W., WRING, S. A., HUMPHREYS, J. E., HUANG, L., MORGAN, J. B., WEBSTER, L. O. and SERABJIT-SINGH, C. S., 2001, Rational use of in vitro P-glycoprotein assays in drug discovery. Journal of Pharmacology and Experimental Therapeutics, 299, 620-628.
25. REGEV, R. and EYTAN, G. D., 1997, Flip-flop of doxorubicin across erythrocyte and lipid membranes. Biochemical Pharmacology, 54, 1151-1158.
26. SAITOH, H. and AUNGST, B. J., 1995, Possible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine. Pharmaceutical Research, 12, 1304-1310.
27. SARKADI, B., MULLER, M., HOMOLYA, L., HOLLO, Z., SEPRODI, J., GERMANN, U. A., GOTTESMAN, M. M., PRICE, E. M. and BOUCHER, R. C., 1994, Interaction of bioactive hydrophobic peptides with the human multidrug transporter. FASEB Journal, 8, 766-770.
28. SAUNA, Z. E. and AMBUDKAR, S. V., 2000, Evidence for a requirement for ATP hydrolysis at two distinct steps during a single turnover of the catalytic cycle of human P-glycoprotein. Proceedings of the National Academy of Sciences, USA, 97, 2515-2520.
29. SAUNA, Z. E. and AMBUDKAR, S. V., 2001, Characterization of the catalytic cycle of ATP hydrolysis by human P-glycoprotein: the two ATP hydrolysis events in a single catalytic cycle are kinetically similar but affect different functional outcomes. Journal of Biological Chemistry, 276, 11653-11661.
30. SCALA, S., AKHMED, N., RAO, U. S., PAULL, K., LAN, L. B., DICKSTEIN, B., LEE, J. S., ELGEMEIE, G. H., STEIN, W. D. and BATES, S. E., 1997, P-glycoprotein substrates and antagonists cluster into two distinct groups. Molecular Pharmacology, 51, 1024-1033.
31. SCHINKEL, A. H., WAGENAAR, E., MoL, C. A. and VAN DEEMTER, L., 1996, P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. Journal of Clinical Investigation, 97, 2517-2524.
32. SCHUETZ, E. G., YASUDA, K., ARIMORI, K. and SCHUETZ, J. D., 1998, Human MDR1 and mouse mdr1a P-glycoprotein alter the cellular retention and disposition of erythromycin, but not of retinoic acid or benzo(a)pyrene. Archives of Biochemistry and Biophysics, 350, 340-347.
33. SHAPIRO, A. B. and LING, V., 1998, Stoichiometry of coupling of rhodamine 123 transport to ATP hydrolysis by P-glycoprotein. European Journal of Biochemistry 254, 189-193.
34. SMIT, J. W., WEERT, B., SCHINKEL, A. H. and MEIJER, D. K., 1998, Heterologous expression of various P-glycoproteins in polarized epithelial cells induces directional transport of small (type 1) and bulky (type 2) cationic drugs. Journal of Pharmacology and Experimental Therapeutics, 286, 321-327.
35. SOARES-DA-SILVA, P. and SERRAO, M. P., 2000, Outward transfer of dopamine precursor L-3,4-dihydroxyphenylalanine (L-dopa) by native and human P-glycoprotein in LLC-PK(1) and LLC-GA5 co1300 renal cells. Journal of Pharmacology and Experimental Therapeutics, 293, 697-704.
36. SONVEAUX, N., VIGANO, C., SHAPIRO, A. B., LING, V. and RUYSSCHAERT, J. M., 1999, Ligand-mediated tertiary structure changes of reconstituted P-glycoprotein. A tryptophan fluorescence quenching analysis. Journal of Biological Chemistry, 274, 17649-17654.
37. STEIN, W. D., 1997, Kinetics of the multidrug transporter (P-glycoprotein) and its reversal. Physiology Reviews, 77, 545-590.
38. TANAKA, K., HIRAI, M., TANIGAWARA, Y., YASUHARA, M., HORI, R., UEDA K. and INUI, K., 1996, Effect of cyclosporin analogues and FK506 on transcellular transport of daunorubicin and vinblastine via P-glycoprotein. Pharmaceutical Research, 13, 1073-1077.
39. URBATSCH, I. L., AL-SHAWI, M. K. and SENIOR, A. E., 1994, Characterization of the ATPase activity of purified Chinese hamster P-glycoprotein. Biochemistry, 33, 7069-7076.
40. WANDEL, C., KIM, R., WOOD, M. and WOOD, A., 2002, Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology, 96, 913-920.
41. WANG, E.-J., CASCIANO, C. N., CLEMENT, R. P. and JOHNSON, W. W., 2000a, Two transport binding sites of P-glycoprotein are unequal yet contingent: initial rate kinetic analysis by ATP hydrolysis demonstrates intersite dependency. Biochimica et Biophysica Acta, 1481, 63-74.
42. WANG, E.-J., CASCIANO, C. N., CLEMENT, R. P. and JOHNSON, W. W., 2000b, Cooperativity in the inhibition of P-glycoprotein-mediated daunorubicin transport: evidence for half-of-the-sites reactivity. Archives of Biochemistry and Biophysics, 383, 91-98.
43. WANG, E.-J., CASCIANO, C. N., CLEMENT, R. P. and JOHNSON, W. W., 2000c, In vitro flow cytometry method to quantitatively assess inhibitors of P-glycoprotein. Drug Metabolism and Disposition, 28, 522-528.
44. WANG, E.-J., CASCIANO, C. N., CLEMENT, R. P. and JOHNSON, W. W., 2001a, HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharmaceutical Research, 18, 800-806.
45. WANG, E.-J., LEW, K., BARRECKI, M., CASCIANO, C. N., CLEMENT, R. P. and JOHNSON, W. W., 2001b, Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4. Chemical Research and Toxicology, 14, 1596-1603.
46. WANG, E.-J., LEW, K., CASCIANO, C. N., CLEMENT, R. P. and JOHNSON, W. W., 2002, Characterization of common, azole antifungals contrasted for interaction with P-glycoprotein. Antimicrobial Agents and Chemotherapy, 46, 160-165.
47. WIELINGA, P. R., WESTERHOFF, H. V. and LANKUELMA, J., 2000, The relative importance of passive and P-glycoprotein mediated anthracycline efflux from multidrug-resistant cells. European Journal of Biochemistry, 267, 649-657.
48. WOLF, D. C. and HORWITZ, S. B., 1992, P-glycoprotein transports corticosterone and is photoaffinity-labeled by the steroid. International Journal of Cancer, 52, 141-146.
49. YANG, J. J., KIM, K. J. and LEE, V. H., 2000, Role of P-glycoprotein in restricting propranolol transport in cultured rabbit conjunctival epithelial cell layers. Pharmaceutical Research, 17, 533-538.
50. YUSA, K. and TSURUO, T., 1989, Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Research, 49, 5002-5006.
51. ZACHOWSKI, A., 1993, Phospholipids in animal eukaryotic membranes: transverse asymmetry and movement. Biochemical Journal, 294, 1-14.
52. ZSCHIRSCHE, M., LEMMA, G. L., KLEBINGAT, K. J., FRANKE, G., TERHAAG, B., HOMANN, A., GRAMATTE, T., KROEMER, H. K. and SEIGMUND, W., 2002, Stereoselective disposition of talinolol in man. Journal of Pharmaceutical Science, 91, 303-311.